194 related articles for article (PubMed ID: 24038157)
1. Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence.
Bauer SR; Richman EL; Sosa E; Weinberg V; Song X; Witte JS; Carroll PR; Chan JM
Prostate; 2013 Dec; 73(16):1786-95. PubMed ID: 24038157
[TBL] [Abstract][Full Text] [Related]
2. Association of variants in two vitamin e transport genes with circulating vitamin e concentrations and prostate cancer risk.
Wright ME; Peters U; Gunter MJ; Moore SC; Lawson KA; Yeager M; Weinstein SJ; Snyder K; Virtamo J; Albanes D
Cancer Res; 2009 Feb; 69(4):1429-38. PubMed ID: 19190344
[TBL] [Abstract][Full Text] [Related]
3. Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.
Nordström T; Van Blarigan EL; Ngo V; Roy R; Weinberg V; Song X; Simko J; Carroll PR; Chan JM; Paris PL
Prostate; 2016 Mar; 76(4):339-48. PubMed ID: 26585352
[TBL] [Abstract][Full Text] [Related]
4. Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.
Chan JM; Darke AK; Penney KL; Tangen CM; Goodman PJ; Lee GM; Sun T; Peisch S; Tinianow AM; Rae JM; Klein EA; Thompson IM; Kantoff PW; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2016 Jul; 25(7):1050-1058. PubMed ID: 27197287
[TBL] [Abstract][Full Text] [Related]
5. Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence.
Gerstenberger JP; Bauer SR; Van Blarigan EL; Sosa E; Song X; Witte JS; Carroll PR; Chan JM
Prostate; 2015 Jan; 75(1):60-9. PubMed ID: 25284284
[TBL] [Abstract][Full Text] [Related]
6. Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study.
Kang D; Lee KM; Park SK; Berndt SI; Peters U; Reding D; Chatterjee N; Welch R; Chanock S; Huang WY; Hayes RB
Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1581-6. PubMed ID: 17646272
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation in myeloperoxidase modifies the association of serum α-tocopherol with aggressive prostate cancer among current smokers.
Cheng TY; Barnett MJ; Kristal AR; Ambrosone CB; King IB; Thornquist MD; Goodman GE; Neuhouser ML
J Nutr; 2011 Sep; 141(9):1731-7. PubMed ID: 21795425
[TBL] [Abstract][Full Text] [Related]
8. Serum α-tocopherol and γ-tocopherol concentrations and prostate cancer risk in the PLCO Screening Trial: a nested case-control study.
Weinstein SJ; Peters U; Ahn J; Friesen MD; Riboli E; Hayes RB; Albanes D
PLoS One; 2012; 7(7):e40204. PubMed ID: 22792240
[TBL] [Abstract][Full Text] [Related]
9. Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival.
Van Blarigan EL; Ma J; Kenfield SA; Stampfer MJ; Sesso HD; Giovannucci EL; Witte JS; Erdman JW; Chan JM; Penney KL
Cancer Epidemiol Biomarkers Prev; 2014 Jun; 23(6):1037-46. PubMed ID: 24711484
[TBL] [Abstract][Full Text] [Related]
10. Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study.
Weinstein SJ; Wright ME; Pietinen P; King I; Tan C; Taylor PR; Virtamo J; Albanes D
J Natl Cancer Inst; 2005 Mar; 97(5):396-9. PubMed ID: 15741576
[TBL] [Abstract][Full Text] [Related]
11. A 28-year prospective analysis of serum vitamin E, vitamin E-related genetic variation and risk of prostate cancer.
Lawrence WR; Lim JE; Huang J; Weinstein SJ; Mӓnnistӧ S; Albanes D
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):553-560. PubMed ID: 35197557
[TBL] [Abstract][Full Text] [Related]
12. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.
Abe M; Xie W; Regan MM; King IB; Stampfer MJ; Kantoff PW; Oh WK; Chan JM
BJU Int; 2011 Jan; 107(1):126-34. PubMed ID: 20477822
[TBL] [Abstract][Full Text] [Related]
13. Effects of polymorphisms in vitamin E-, vitamin C-, and glutathione peroxidase-related genes on serum biomarkers and associations with glaucoma.
Zanon-Moreno V; Asensio-Marquez EM; Ciancotti-Oliver L; Garcia-Medina JJ; Sanz P; Ortega-Azorin C; Pinazo-Duran MD; Ordovás JM; Corella D
Mol Vis; 2013; 19():231-42. PubMed ID: 23401652
[TBL] [Abstract][Full Text] [Related]
14. Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.
Key TJ; Appleby PN; Travis RC; Albanes D; Alberg AJ; Barricarte A; Black A; Boeing H; Bueno-de-Mesquita HB; Chan JM; Chen C; Cook MB; Donovan JL; Galan P; Gilbert R; Giles GG; Giovannucci E; Goodman GE; Goodman PJ; Gunter MJ; Hamdy FC; Heliövaara M; Helzlsouer KJ; Henderson BE; Hercberg S; Hoffman-Bolton J; Hoover RN; Johansson M; Khaw KT; King IB; Knekt P; Kolonel LN; Le Marchand L; Männistö S; Martin RM; Meyer HE; Mondul AM; Moy KA; Neal DE; Neuhouser ML; Palli D; Platz EA; Pouchieu C; Rissanen H; Schenk JM; Severi G; Stampfer MJ; Tjønneland A; Touvier M; Trichopoulou A; Weinstein SJ; Ziegler RG; Zhou CK; Allen NE;
Am J Clin Nutr; 2015 Nov; 102(5):1142-57. PubMed ID: 26447150
[TBL] [Abstract][Full Text] [Related]
15. Genetic variants reflecting higher vitamin e status in men are associated with reduced risk of prostate cancer.
Major JM; Yu K; Weinstein SJ; Berndt SI; Hyland PL; Yeager M; Chanock S; Albanes D
J Nutr; 2014 May; 144(5):729-33. PubMed ID: 24623848
[TBL] [Abstract][Full Text] [Related]
16. Manganese superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland).
Woodson K; Tangrea JA; Lehman TA; Modali R; Taylor KM; Snyder K; Taylor PR; Virtamo J; Albanes D
Cancer Causes Control; 2003 Aug; 14(6):513-8. PubMed ID: 12948282
[TBL] [Abstract][Full Text] [Related]
17. Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy.
Huang SP; Huang CY; Wu WJ; Pu YS; Chen J; Chen YY; Yu CC; Wu TT; Wang JS; Lee YH; Huang JK; Huang CH; Wu MT
Int J Cancer; 2006 Oct; 119(8):1902-7. PubMed ID: 16708371
[TBL] [Abstract][Full Text] [Related]
18. Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.
Huang JG; Pedersen J; Hong MK; Harewood LM; Peters J; Costello AJ; Hovens CM; Corcoran NM
BJU Int; 2013 May; 111(6):921-7. PubMed ID: 23350712
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
20. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.
Chan JM; Oh WK; Xie W; Regan MM; Stampfer MJ; King IB; Abe M; Kantoff PW
J Clin Oncol; 2009 Aug; 27(22):3577-83. PubMed ID: 19528373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
